TCR² Presentations at American Association of Cancer Research (AACR) Annual Meeting 2021 to Highlight Solid Tumor Pipeline
TCR2 Therapeutics Inc. (Nasdaq: TCRR) announced three e-poster presentations showcasing new clinical data from the Phase 1 trial of gavo-cel for treatment-refractory mesothelin-expressing solid tumors, to be presented at the AACR Virtual Annual Meeting from April 10-15, 2021. Key presentations include data on gavo-cel's preliminary safety and efficacy, and engineering off-the-shelf TRuC-T cells. The trial aims to leverage TRuC technology for enhanced anti-tumor activity and lower cytokine release compared to traditional CAR-T cells.
- Presentation of new clinical data supporting gavo-cel's efficacy in treating solid tumors.
- Engagement at the esteemed AACR Virtual Annual Meeting for broader visibility.
- Demonstration of TRuC technology's potential superiority over CAR-T cells in preliminary studies.
- None.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that three e-poster presentations featuring new clinical data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for treatment refractory mesothelin-expressing solid tumors and preclinical data on its pipeline programs will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place April 10-15, 2021.
Abstracts can be found at www.aacr.org and include the following e-poster presentations below.
Title: Preliminary Safety and Efficacy of gavocabtagene autoleucel (gavo-cel, TC-210), a T Cell Receptor Fusion Construct (TRuC®), in Patients with Treatment Refractory Mesothelin Overexpressing Solid Tumors
Poster: CT105
Session: Phase 1 Clinical Trials
Title: Engineering Off-the-shelf T Cell Receptor Fusion Construct (TRuC) T Cells
Poster: 1514
Session: Adoptive Cell Therapy
This e-poster presentation will highlight allogeneic (off-the-shelf) TRuC-T cells targeting mesothelin that utilized a CRISPR/Cas9 endonucleases approach, yielding fully functional TRuCs that lack alloreactivity and reduced risk of host rejection while maintaining upregulation of activation markers, secretion of cytokines and clearance of tumor cells comparable to autologous TRuC-T cells targeting mesothelin.
Title: Discovery and Preclinical Characterization of Fratricide-resistant TRuC-T Cells Targeting CD70
Poster: 1528
Session: Adoptive Cell Therapy
This e-poster presentation will highlight fratricide-resistant CD70-directed TRuC-T cells, which demonstrated an improved memory phenotype and significant anti-tumor efficacy in multiple xenograft mouse models with no evidence of in vivo fratricide.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.
Forward-looking Statements
This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of TC-210, timing for interim updates for the TC-210 and TC-110 clinical trials, timing for the certification of our manufacturing facility in Stevenage, UK, increased manufacturing capacity and technical capabilities, including relating to our manufacturing partnership with ElevateBio, LLC, increased clinical trial demand, future IND filings and clinical development plans, the development of the Company’s TRuC-T cells, their potential characteristics, applications and clinical utility, and the potential therapeutic applications of the Company’s TRuC-T cell platform.
The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2’s ability to secure additional manufacturing facilities; whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor and Media Contact:
Carl Mauch
Director, Investor Relations and Corporate Communications
TCR2 Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com
FAQ
What is TCRR's latest clinical trial presented at AACR 2021?
When will TCRR present its findings at the AACR meeting?
What are the key topics of TCRR's e-poster presentations?
How does TCRR's TRuC technology differ from CAR-T cells?
